Omalizumab-A Review.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

1. Efficacy and safety of different doses of ligelizumab in patients with chronic spontaneous urticaria: a systematic review and meta-analysis of randomized controlled trials with GRADE evaluation.Naunyn-Schmiedeberg's archives of pharmacology · 2026
   Pooled it
2. Basophils in atopic dermatitis: Immunologic roles and clinical implications.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2026
   Review
3. From skin to lung: basophil-mediated spread of allergic diseases.Frontiers in immunology · 2026
   Review
4. Urticaria Voices: Real-World Treatment Patterns and Outcomes in Chronic Spontaneous Urticaria.Dermatology and therapy · 2025
   Article
5. Tiny Troublemakers-A Comprehensive Approach to Crusted Scabies.Diagnostics (Basel, Switzerland) · 2025
   Article
6. GAClinical and translational allergy · 2024
   Review
7. Cost-effectiveness analysis of dupilumab among patients with uncontrolled severe asthma using LIBERTY ASTHMA QUEST Korean data.Health economics review · 2024
   Article
8. Real-Life Effects of Omalizumab on Chronic Rhinosinusitis with Nasal Polyposis.Journal of personalized medicine · 2023
   Article
9. Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria.International journal of molecular sciences · 2023
   Review
10. Considerations for shared decision-making in treatment of chronic rhinosinusitis with nasal polyps.Frontiers in allergy · 2023
    Review
11. Molecular targets for cystic fibrosis and therapeutic potential of monoclonal antibodies.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022
    Review
12. Efficacy and Safety of Biologic Agents in Chronic Urticaria, Asthma and Atopic Dermatitis - A Real-life Experience.The open respiratory medicine journal · 2020
    Article
13. Systemic Treatment of Adult Atopic Dermatitis: A Review.Dermatology and therapy · 2017
    Review
14. Treatment of Chronic Spontaneous Urticaria with a Single Dose of Omalizumab: A Study of Four Cases.Indian journal of dermatology
    Article
15. Acute Interstitial Nephritis: A Rare and Unusual Side Effect of Omalizumab.Journal of investigative medicine high impact case reports
    Article
16. Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients.Indian dermatology online journal
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as